Developer docs
API playgroundTry for free, no card

Search company profiles

CNX Therapeutics

Full company profile

uuid00067ly

Namestring
CNX Therapeutics
Legal namestring
CNX Therapeutics Limited
Company typeenum
Private
Founded yearint
2021
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
specialty pharmaceuticals, CNS therapeutics, critical care medicines, pharmaceutical distribution, drug licensing
Industry2 codes
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing32541
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Specialty Pharmaceuticals
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Product Licensing and Distribution
TypeLicensing Royalties
Description

CNX licenses and distributes pharmaceutical products for CNS, critical care, and other conditions across 60+ markets globally through direct operations and strategic partnerships.

cnx-therapeutics.com
2Acquisition and Integration
TypeOne Time License
Description

Growth strategy based on acquiring established pharmaceutical brands from larger companies and integrating them into CNX's European commercial platform.

cnx-therapeutics.com
3Licensing Deals
TypeLicensing Royalties
Description

Exclusive rights to market and sell licensed products across European markets, with upfront payments and potential milestone payments. Example: EUR 750,000 upfront for Sumatriptan Alginate Film from Klaria.

cnx-therapeutics.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Supply Chain, Operations, Marketing or Sales, Technology or R&D
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Ethyol
Description

FDA-approved cytoprotective agent indicated to reduce cumulative renal toxicity associated with cisplatin chemotherapy and reduce xerostomia in head and neck cancer patients.

cnx-therapeutics.com
+2 more records
Core offering1 text field

CNX Therapeutics licenses, distributes, and commercializes a portfolio of specialty medicines focused on Central Nervous System (CNS), critical care, and oncology support conditions. The company operates a buy-and-build platform model that acquires and in-licenses established pharmaceutical brands from larger pharmaceutical companies that choose to divest non-core assets, supplying 25+ products across 60+ markets. It also develops proprietary value-added medicines (VAM), including a novel Sumatriptan Alginate Film for migraine.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • First UK pharma company to achieve B Corp certification with score of 103.2
+2 more records
Product overview1 text field

CNX Therapeutics is a specialty pharmaceutical company that commercializes and distributes a portfolio of medicines for central nervous system (CNS), critical care, and other therapeutic conditions. The company operates a platform-based model with over 20 marketed products (including 14 injectables and 6 CNS products) distributed across 60+ markets globally. The portfolio consists of acquired branded products (Sativex®, Ethyol®, Tacrolimus infusion), licensed products (Sumatriptan Alginate Film), and value-added medicines (controlled-release formulations), supplemented by strategic acquisitions of companies (Synchrony Pharma) and product portfolios from major pharma companies (Eisai, Sanofi, Clinigen). Products are distributed both directly and through strategic partnerships, with a focus on hospital-initiated treatments in CNS, critical care, and oncology.

Product and service8 records
1Sativex (nabiximols)
CategorySpecialty Pharmaceuticals - CNS
Description

Sativex (nabiximols) is an oromucosal cannabis-based spray indicated as add-on treatment for multiple sclerosis (MS) spasticity in adult patients. It is sold to healthcare providers, hospitals, and specialty pharmacies treating MS patients.

2Ethyol (amifostine)
CategorySpecialty Pharmaceuticals - Oncology Support
Description

Ethyol (amifostine) is a cytoprotective agent used to reduce cumulative renal toxicity associated with repeated cisplatin administration in advanced ovarian cancer, and to reduce the incidence of moderate-to-severe xerostomia in patients receiving postoperative radiation for head and neck cancer. It is sold to oncology hospitals and treatment centers.

3Tacrolimus 5 mg/ml Concentrate for Solution for Infusion
CategorySpecialty Pharmaceuticals - Critical Care / Transplantation
Description

Tacrolimus 5 mg/ml concentrate is an immunosuppressant infusion used for prophylaxis of transplant rejection in adult and pediatric patients receiving allogeneic liver, kidney, or heart transplants. It is supplied to transplant hospitals and specialist healthcare providers.

4Sumatriptan Alginate Film (migraine therapy)
CategorySpecialty Pharmaceuticals - CNS / Value-Added Medicines
Description

Sumatriptan Alginate Film is a value-added medicine (VAM) formulation of sumatriptan delivered via a proprietary alginate-based oral trans-mucosal film technology for acute migraine treatment. It is targeted at healthcare providers, neurologists, and patients seeking faster-acting migraine relief than conventional oral sumatriptan tablets.

5Loxapac and Parkinane LP (Eisai CNS Portfolio)
CategorySpecialty Pharmaceuticals - CNS
Description

Loxapac (loxapine) is an antipsychotic used in schizophrenia and acute agitation, and Parkinane LP (trihexyphenidyl) is an anticholinergic used in Parkinson's disease. Both are sold to mental health hospitals, neurologists, and specialty psychiatry clinics.

6Clinigen Cancer Support Therapies portfolio
CategorySpecialty Pharmaceuticals - Oncology Support
Description

Clinigen Cancer Support Therapies is a portfolio of oncology supportive care medicines used to manage side effects and complications of cancer treatment, sold to oncology hospitals and treatment centers.

7Sanofi CNS Portfolio brands
CategorySpecialty Pharmaceuticals - CNS
Description

The Sanofi CNS Portfolio comprises multiple established CNS medicines for conditions including anxiety, depression, and epilepsy, sold to hospitals, psychiatrists, neurologists, and specialty pharmacies across multiple markets.

8Controlled-release value-added medicine for pain
CategorySpecialty Pharmaceuticals - Value-Added Medicines / Pain
Description

A controlled-release value-added medicine (VAM) formulation for pain management being developed by CNX to improve dosing convenience and patient outcomes versus existing pain therapies. Targeted at healthcare providers and pain specialists.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-06-26
Description

US commercial partnership for launch of Ethyol (amifostine) in July 2026. Legacy Pharma, a specialty pharmaceutical distribution platform, commercializes amifostine across the United States through specialty pharmacy and traditional wholesale channels. This is CNX's first commercial partnership in the United States.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2026-04-02
Description

Acquired rights to Tacrolimus 5 mg/ml concentrate for solution for infusion, the first generic version of Prograf (Astellas Pharma). Transaction signed April 1, 2026.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-11-03
Description

Existing commercial partner for Sativex (nabiximols) in European markets. Almirall holds commercial rights for the product in key European territories.

Strategic tierFormerTypeOthersAnnounced on2025-11-03
Description

Sativex acquired from Jazz Pharmaceuticals in October 2025. Jazz provided transition support under a Transition Service Agreement during the handover.

5IHP (International Health Partners)
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2025-04-01
Description

Partnership to expand global medicine access, working together to ensure essential medicines reach patients in underserved markets.

cnx-therapeutics.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-13
Description

Strategic licensing deal for Sumatriptan Alginate Film across Europe (EU markets, UK, Norway, Switzerland) with initial focus on Germany, Spain, Italy. Klaria received EUR 750,000 upfront payment. CNX has exclusive rights to market and sell the product.

Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Partnership bringing five interns from underrepresented backgrounds into 12-month roles across HR, Legal, Quality, Data, and Commercial teams. Expanded to include work placement and mentoring programme in 2026.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

UK- and Europe-focused specialty pharma platform with a comparable buy-and-build strategy of acquiring mature, off-patent and divested brands from larger pharma companies. Directly comparable business model to CNX, including recent Tacrolimus acquisition (counterparty to CNX).

TypeBroad incumbent
Description

German-headquartered European specialty and generics pharmaceutical company with a broad portfolio of branded specialty products and generics across CNS, critical care and hospital injectables — overlapping with CNX's therapeutic focus and geographic footprint but at significantly larger scale.

TypeBroad incumbent
Description

Italian specialty pharmaceutical group with a strong European presence in CNS, rare diseases and hospital products. Comparable focus on specialty branded medicines across multiple European geographies, though materially larger and more diversified than CNX.

TypeDirect peer
Description

Spanish specialty pharmaceutical company focused on medical dermatology and specialty care across Europe; existing commercial partner of CNX for Sativex. Operates a similar European specialty pharma model with focused therapeutic categories and partnered distribution.

TypeDirect peer
Description

UK and Ireland-headquartered specialty pharmaceutical company marketing established prescription medicines across CNS, pain and women's health. Closely comparable business model of acquiring and commercializing mature specialty brands in European markets.

TypeDirect peer
Description

European specialty pharmaceutical company headquartered in the Netherlands with a focus on hospital and specialty products including gastroenterology and CNS. Comparable European-focused, specialty branded pharma model with strong hospital channel presence.

TypeBroad incumbent
Description

UK-listed specialty generics and branded pharmaceutical company with significant European and Middle East presence. Comparable in product categories (CNS, hospital injectables) and in acquiring/integrating mature assets, though substantially larger and more diversified geographically.

TypeBroad incumbent
Description

Swedish specialty pharmaceutical company focused on rare diseases and specialty care across Europe and globally. Comparable in being a Europe-headquartered specialty pharma platform with acquired and licensed products across therapeutic niches.

TypeDirect peer
Description

Ireland-headquartered specialty pharmaceutical company marketing branded prescription medicines in CNS, women's health and urology across European markets. Directly comparable in size, therapeutic focus and European specialty pharma model.

TypeRegional player
Description

Japan-based specialty pharmaceutical company with growing European operations focused on CNS and rare disease specialty products. Comparable in CNS therapeutic focus and value-added specialty product positioning, though anchored in a different primary geography.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CNX Therapeutics

Specialty Pharmaceuticalscnx-therapeutics.com

CNX Therapeutics firmographics

Firmographics
Name
CNX Therapeutics
Legal name
CNX Therapeutics Limited
Website
https://cnx-therapeutics.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

CNX Therapeutics industry classification

Industry
Product category
Specialty Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Specialty pharmaceuticals
  • CNS therapeutics
  • Critical care medicines
  • Pharmaceutical distribution
  • Drug licensing

Where CNX Therapeutics is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

CNX Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Supply Chain, Operations, Marketing or Sales, Technology or R&D

Revenue model

  1. Product Licensing and Distribution: CNX licenses and distributes pharmaceutical products for CNS, critical care, and other conditions across 60+ markets globally through direct operations and strategic partnerships.
  2. Acquisition and Integration: Growth strategy based on acquiring established pharmaceutical brands from larger companies and integrating them into CNX's European commercial platform.
  3. Licensing Deals: Exclusive rights to market and sell licensed products across European markets, with upfront payments and potential milestone payments. Example: EUR 750,000 upfront for Sumatriptan Alginate Film from Klaria.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels4 records

CNX Therapeutics product offering

Product offering

Core offering

CNX Therapeutics licenses, distributes, and commercializes a portfolio of specialty medicines focused on Central Nervous System (CNS), critical care, and oncology support conditions. The company operates a buy-and-build platform model that acquires and in-licenses established pharmaceutical brands from larger pharmaceutical companies that choose to divest non-core assets, supplying 25+ products across 60+ markets. It also develops proprietary value-added medicines (VAM), including a novel Sumatriptan Alginate Film for migraine.

Product overview

CNX Therapeutics is a specialty pharmaceutical company that commercializes and distributes a portfolio of medicines for central nervous system (CNS), critical care, and other therapeutic conditions. The company operates a platform-based model with over 20 marketed products (including 14 injectables and 6 CNS products) distributed across 60+ markets globally. The portfolio consists of acquired branded products (Sativex®, Ethyol®, Tacrolimus infusion), licensed products (Sumatriptan Alginate Film), and value-added medicines (controlled-release formulations), supplemented by strategic acquisitions of companies (Synchrony Pharma) and product portfolios from major pharma companies (Eisai, Sanofi, Clinigen). Products are distributed both directly and through strategic partnerships, with a focus on hospital-initiated treatments in CNS, critical care, and oncology.

Differentiator

Problem solved

Functional benefit

Brands

  • Ethyol: FDA-approved cytoprotective agent indicated to reduce cumulative renal toxicity associated with cisplatin chemotherapy and reduce xerostomia in head and neck cancer patients.
  • Sativex (nabiximols)
  • Tacrolimus Infusion

Products and services

  • Sativex (nabiximols) Sativex (nabiximols) is an oromucosal cannabis-based spray indicated as add-on treatment for multiple sclerosis (MS) spasticity in adult patients. It is sold to healthcare providers, hospitals, and specialty pharmacies treating MS patients.
  • Ethyol (amifostine) Ethyol (amifostine) is a cytoprotective agent used to reduce cumulative renal toxicity associated with repeated cisplatin administration in advanced ovarian cancer, and to reduce the incidence of moderate-to-severe xerostomia in patients receiving postoperative radiation for head and neck cancer. It is sold to oncology hospitals and treatment centers.
  • Tacrolimus 5 mg/ml Concentrate for Solution for Infusion Tacrolimus 5 mg/ml concentrate is an immunosuppressant infusion used for prophylaxis of transplant rejection in adult and pediatric patients receiving allogeneic liver, kidney, or heart transplants. It is supplied to transplant hospitals and specialist healthcare providers.
  • Sumatriptan Alginate Film (migraine therapy) Sumatriptan Alginate Film is a value-added medicine (VAM) formulation of sumatriptan delivered via a proprietary alginate-based oral trans-mucosal film technology for acute migraine treatment. It is targeted at healthcare providers, neurologists, and patients seeking faster-acting migraine relief than conventional oral sumatriptan tablets.
  • Loxapac and Parkinane LP (Eisai CNS Portfolio) Loxapac (loxapine) is an antipsychotic used in schizophrenia and acute agitation, and Parkinane LP (trihexyphenidyl) is an anticholinergic used in Parkinson's disease. Both are sold to mental health hospitals, neurologists, and specialty psychiatry clinics.
  • Clinigen Cancer Support Therapies portfolio Clinigen Cancer Support Therapies is a portfolio of oncology supportive care medicines used to manage side effects and complications of cancer treatment, sold to oncology hospitals and treatment centers.
  • Sanofi CNS Portfolio brands The Sanofi CNS Portfolio comprises multiple established CNS medicines for conditions including anxiety, depression, and epilepsy, sold to hospitals, psychiatrists, neurologists, and specialty pharmacies across multiple markets.
  • Controlled-release value-added medicine for pain A controlled-release value-added medicine (VAM) formulation for pain management being developed by CNX to improve dosing convenience and patient outcomes versus existing pain therapies. Targeted at healthcare providers and pain specialists.

Quantifiable outcome

  • First UK pharma company to achieve B Corp certification with score of 103.2
  • +2 more outcomes

Companies that use CNX Therapeutics

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles2 records

CNX Therapeutics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

CNX Therapeutics partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core, former and supporting.

  • Legacy Pharma Inc. SEZCcoreChannel Partner/ Reseller/ Distributor · 26 June 2026US commercial partnership for launch of Ethyol (amifostine) in July 2026. Legacy Pharma, a specialty pharmaceutical distribution platform, commercializes amifostine across the United States through specialty pharmacy and traditional wholesale channels. This is CNX's first commercial partnership in the United States.
  • PharmanoviacoreOEM/ Whitelabel/ Licensing Partner · 2 April 2026Acquired rights to Tacrolimus 5 mg/ml concentrate for solution for infusion, the first generic version of Prograf (Astellas Pharma). Transaction signed April 1, 2026.
  • AlmirallcoreChannel Partner/ Reseller/ Distributor · 3 November 2025Existing commercial partner for Sativex (nabiximols) in European markets. Almirall holds commercial rights for the product in key European territories.
  • Jazz PharmaceuticalsformerOthers · 3 November 2025Sativex acquired from Jazz Pharmaceuticals in October 2025. Jazz provided transition support under a Transition Service Agreement during the handover.
  • IHP (International Health Partners)supportingStrategic or Co-development Partner · 1 April 2025Partnership to expand global medicine access, working together to ensure essential medicines reach patients in underserved markets.
  • Klaria Pharma Holding ABcoreStrategic or Co-development Partner · 13 January 2025Strategic licensing deal for Sumatriptan Alginate Film across Europe (EU markets, UK, Norway, Switzerland) with initial focus on Germany, Spain, Italy. Klaria received EUR 750,000 upfront payment. CNX has exclusive rights to market and sell the product.
  • Social Mobility FoundationsupportingStrategic or Co-development Partner · 1 January 2024Partnership bringing five interns from underrepresented backgrounds into 12-month roles across HR, Legal, Quality, Data, and Commercial teams. Expanded to include work placement and mentoring programme in 2026.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

CNX Therapeutics competitors and assessment

Company assessment

Direct peers

  • Pharmanovia: UK- and Europe-focused specialty pharma platform with a comparable buy-and-build strategy of acquiring mature, off-patent and divested brands from larger pharma companies. Directly comparable business model to CNX, including recent Tacrolimus acquisition (counterparty to CNX).
  • Almirall: Spanish specialty pharmaceutical company focused on medical dermatology and specialty care across Europe; existing commercial partner of CNX for Sativex. Operates a similar European specialty pharma model with focused therapeutic categories and partnered distribution.
  • Galen: UK and Ireland-headquartered specialty pharmaceutical company marketing established prescription medicines across CNS, pain and women's health. Closely comparable business model of acquiring and commercializing mature specialty brands in European markets.
  • Norgine: European specialty pharmaceutical company headquartered in the Netherlands with a focus on hospital and specialty products including gastroenterology and CNS. Comparable European-focused, specialty branded pharma model with strong hospital channel presence.
  • Consilient Health: Ireland-headquartered specialty pharmaceutical company marketing branded prescription medicines in CNS, women's health and urology across European markets. Directly comparable in size, therapeutic focus and European specialty pharma model.

Broad incumbents

  • Stada Arzneimittel: German-headquartered European specialty and generics pharmaceutical company with a broad portfolio of branded specialty products and generics across CNS, critical care and hospital injectables — overlapping with CNX's therapeutic focus and geographic footprint but at significantly larger scale.
  • Recordati: Italian specialty pharmaceutical group with a strong European presence in CNS, rare diseases and hospital products. Comparable focus on specialty branded medicines across multiple European geographies, though materially larger and more diversified than CNX.
  • Hikma Pharmaceuticals: UK-listed specialty generics and branded pharmaceutical company with significant European and Middle East presence. Comparable in product categories (CNS, hospital injectables) and in acquiring/integrating mature assets, though substantially larger and more diversified geographically.
  • Sobi (Swedish Orphan Biovitrum): Swedish specialty pharmaceutical company focused on rare diseases and specialty care across Europe and globally. Comparable in being a Europe-headquartered specialty pharma platform with acquired and licensed products across therapeutic niches.

Regional players

  • Kyowa Kirin: Japan-based specialty pharmaceutical company with growing European operations focused on CNS and rare disease specialty products. Comparable in CNS therapeutic focus and value-added specialty product positioning, though anchored in a different primary geography.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

CNX Therapeutics social profiles

Digital presence

CNX Therapeutics compliance and trust

Trust signal

Compliance3 records

CNX Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CNX Therapeutics leadership team

Management profile

Number of profiles

Profiles12 records

CNX Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

CNX Therapeutics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CNX Therapeutics M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CNX Therapeutics

What does CNX Therapeutics do?

CNX Therapeutics licenses, distributes, and commercializes a portfolio of specialty medicines focused on Central Nervous System (CNS), critical care, and oncology support conditions. The company operates a buy-and-build platform model that acquires and in-licenses established pharmaceutical brands from larger pharmaceutical companies that choose to divest non-core assets, supplying 25+ products across 60+ markets. It also develops proprietary value-added medicines (VAM), including a novel Sumatriptan Alginate Film for migraine.

Is CNX Therapeutics a public or private company?

CNX Therapeutics is a private company. It is classified as private equity controlled and is currently operating.

When was CNX Therapeutics founded?

CNX Therapeutics was founded in 2021. It employs 51 to 100 people.

Where is CNX Therapeutics based?

CNX Therapeutics is headquartered in London, United Kingdom, in the Europe region.

How does CNX Therapeutics make money?

Three revenue lines are on record. Product Licensing and Distribution is the primary driver. The others are acquisition and Integration and licensing Deals.

Who are CNX Therapeutics's main competitors?

Direct peers on record are Pharmanovia, Almirall, Galen, Norgine and Consilient Health. Broad incumbents are Stada Arzneimittel, Recordati, Hikma Pharmaceuticals and Sobi (Swedish Orphan Biovitrum). Kyowa Kirin is listed as a regional player.

Does CNX Therapeutics have an API?

No public API is recorded for CNX Therapeutics.

What industry is CNX Therapeutics in?

CNX Therapeutics's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
news.cision.comKlaria's chairman interviewed on the upcoming European launch of SAF and the potential in the U.S.Klaria's chairman Fredrik Hübinette was interviewed on the European launch of Sumatriptan Alginate Film (SAF) with CNX Therapeutics, expecting milestone and royalty revenues over the next 12 months. CNX aims for a 10-30% European market share of a SEK 1 billion market, while L.E.K. Consulting estimates USD 500 million in global peak sales. Klaria is also conducting a rights issue from 14 to 28 October 2026.news.cision.comKlaria Pharma: External valuation estimates peak sales for Sumatriptan Alginate Film at approx. USD 500 million per yearKlaria Pharma published an external valuation by L.E.K. Consulting estimating peak sales for its Sumatriptan Alginate Film at approximately USD 500 million per year. The company expects milestone payments and royalties from licensing partner CNX Therapeutics for European markets, with a launch planned in the near future. Klaria is also evaluating strategic transactions with BDO.news.cision.comKlaria Pharma Holding AB (publ) calls an Extraordinary General Meeting to resolve on a Rights Issue of units and an amendment of the Articles of AssociationKlaria Pharma Holding AB's board resolved to convene an extraordinary general meeting on 5 October 2026 to approve a rights issue of units at 2.40 SEK per unit, offering a 26% discount. The issue could raise about SEK 148 million, with proceeds intended to support the planned European launch of its migraine product SAF in Q4 2026.The Pharma LetterCNX and Legacy set July US relaunch for EthyolCNX Therapeutics and Legacy Pharma have entered into a US commercial partnership to relaunch Ethyol (amifostine), with the product expected to be available from July 2026. The agreement marks CNX's first commercial partnership in the United States, representing a strategic market entry for the London-based specialty pharmaceutical company. The partnership will see Legacy Pharma handling commercial activities for the drug launch in the US market.NasdaqKlaria receives 25 MSEK in loan financing with the possibility of an additional 15 MSEKKlaria Pharma Holding AB secured a 25 MSEK bridge loan from a Swedish finance company, with an option for an additional 15 MSEK, totaling 40 MSEK. The loan, disbursed immediately, runs until May 27, 2027, and supports preparations for CNX Therapeutics' Sumatriptan Alginate Film launch in Europe.openPR.comMuscle Spasticity Market: Analysis of Growth Patterns, Segment Details, and Competitive ApproachesThe muscle spasticity market is projected to reach $6.91 billion by 2030, growing at a compound annual growth rate of 8.7%, driven by advancements in drug delivery technologies, increasing adoption of botox-based treatments, and expanded neurological healthcare investment. In a notable November 2025 transaction, UK-based specialty pharmaceutical firm CNX Therapeutics acquired Sativex (nabiximols) from Jazz Pharmaceuticals plc to expand CNX's central nervous system portfolio with a plant-based treatment for muscle spasticity in multiple sclerosis patients.PharmiWeb.comCNX Therapeutics acquires Tacrolimus infusion from Pharmanovia, strengthening Critical Care portfolioCNX Therapeutics Limited announced on April 2, 2026 that it has acquired the rights to Tacrolimus 5 mg/ml concentrate for solution for infusion from Pharmanovia, with the transaction signed on April 1, 2026. Tacrolimus infusion is used in hospital settings to prevent organ rejection in liver, kidney, and heart transplant patients, representing the first generic version of the originator product Prograf (Astellas Pharma). Commercial launch is planned across Germany, France, and Spain, with the UK to follow, supporting CNX Therapeutics' strategy to build a leading European specialty pharmaceutical platform focused on Critical Care and CNS.PharmiWeb.comCNX Therapeutics appoints Erin Federman as non-executive directorCNX Therapeutics, a European specialty pharmaceutical company, announced the appointment of Erin Federman as a non-executive director effective 1 March 2026. Federman brings over two decades of experience in global commercial strategy from senior roles at STADA, Novo Nordisk, and Mylan, along with current positions as a strategic advisor in the life sciences sector. The company, which was acquired by Inflexion Private Equity in 2021 and selected for its £2.3bn continuation fund in 2025, noted the appointment as part of its growth strategy across Europe.PharmiWeb.comCNX Therapeutics acquires Sativex® global business from Jazz PharmaceuticalsUK-based specialty pharmaceutical company CNX Therapeutics has agreed to acquire the global rights to Sativex (nabiximols) from Jazz Pharmaceuticals. The deal transfers the worldwide business of the cannabinoid-based medicine, approved for moderate to severe spasticity in adult patients, deepening CNX's focus on central nervous system therapies while allowing Jazz to streamline its portfolio. The transaction reinforces the trend of established pharmaceutical companies reallocating mature assets to leaner, regionally focused players.